BAMBIGRILLEYBAMBI GRILLEY0.000000000000000.000000000000003470GRILLEY, BAMBI0000-0003-4800-6439Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:orcidIdORCID idvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAuthorship 157386Authorship 157388Authorship 157389Authorship 157390Authorship 157391Authorship 157393Authorship 157394Authorship 157395Authorship 157396Authorship 157397Authorship 157398Authorship 157399Authorship 157400Authorship 157401Authorship 157402Authorship 157403Authorship 157404Grilley BJSoCRA SourceSubmitting and Conducting a Sponsor-Investigator IND: Lessons Learned...The Hard Way. SoCRA Source. 2012; (72):26-32.2012-05-01T00:00:002012Submitting and Conducting a Sponsor-Investigator IND: Lessons Learned...The Hard WayGrilley, BJ; Berg, S; Boudreaux, C. Regulatory and Ethical Issues in the Treatment of ChildrenRegulatory and Ethical Issues in the Treatment of Children. 2007.2007-01-01T00:00:002007Regulatory and Ethical Issues in the Treatment of ChildrenGrilley BJNCURA NewsletterData Safety Monitoring: A Practical Guide for Clinical Researchers. NCURA Newsletter. 2006; XXXVIII:6-7.2006-02-01T00:00:002006Data Safety Monitoring: A Practical Guide for Clinical ResearchersNoel, F; Grilley, BJACRP MonitorA Peer Reviewed Quality Assurance Program at a Clinical Research Site. ACRP Monitor. 2006; 1-5.2006-02-01T00:00:002006A Peer Reviewed Quality Assurance Program at a Clinical Research SiteGrilley BJClinical Trials AdministratorImprove Quality with a Trial Monitoring Program. Clinical Trials Administrator. 2005; 3:127-130.2005-11-01T00:00:002005Improve Quality with a Trial Monitoring ProgramGrilley BJClinical Trials AdministratorData Review Committees Offer Additional Protection. Clinical Trials Administrator. 2005; 3:101-102.2005-09-01T00:00:002005Data Review Committees Offer Additional ProtectionGrilley BJInvestigational Drugs in the Principles and Practice of Drug InformationDrug Information: A Guide for Pharmacists. Investigational Drugs in the Principles and Practice of Drug Information. 2014.2014-01-01T00:00:002014Drug Information: A Guide for Pharmacists
Grilley BJRegulations Governing Clinical Trials in Gene TherapyCancer Gene Therapy by Viral and Non-viral Vectors. Regulations Governing Clinical Trials in Gene Therapy. 2014.2014-01-01T00:00:002014Cancer Gene Therapy by Viral and Non-viral VectorsGrilley, BJ
Investigational Drugs in the Principles and Practice of Drug InformationDrug Information: A Guide for Pharmacists. Investigational Drugs in the Principles and Practice of Drug Information. 2012.2012-01-01T00:00:002012Drug Information: A Guide for PharmacistsGrilley, BJGene Therapy OversightStudy Guide for Institutional Review Board Management and Function. Gene Therapy Oversight. 2005.2005-01-01T00:00:002005Study Guide for Institutional Review Board Management and FunctionGrilley, BJ
Gene Therapy OversightInstitutional Review Board: Management and Function. Gene Therapy Oversight. 2006.2006-01-01T00:00:002006Institutional Review Board: Management and FunctionGrilley BJInvestigational Drugs in the Principles and Practice of Drug InformationDrug Information: A Guide for Pharmacists. Investigational Drugs in the Principles and Practice of Drug Information. 2006.2006-01-01T00:00:002006Drug Information: A Guide for PharmacistsGrilley, BJGene Therapy OversightStudy Guide for Institutional Review Board: Management and Function. Gene Therapy Oversight. 2002.2002-01-01T00:00:002002Study Guide for Institutional Review Board: Management and FunctionGrilley, BJGene Therapy OversightInstitutional Review Board: Management and Function. Gene Therapy Oversight. 2002.2002-01-01T00:00:002002Institutional Review Board: Management and FunctionGrilley, BJInvestigational Drugs in the Principles and Practice of Drug InformationDrug Information: A Guide for Pharmacists. Investigational Drugs in the Principles and Practice of Drug Information. 2001.2001-01-01T00:00:002001Drug Information: A Guide for PharmacistsGrilley, BJInvestigational Drugs in the Principles and Practice of Drug InformationDrug Information: A Guide for Pharmacists. Investigational Drugs in the Principles and Practice of Drug Information. 1996.1996-01-01T00:00:001996Drug Information: A Guide for PharmacistsGrilley, BJThe Cancer BulletinFludarabine phosphate: a new agent for lymphoproliferative malignancies. The Cancer Bulletin. 1991; 43:583-584.1991-01-01T00:00:001991Fludarabine phosphate: a new agent for lymphoproliferative malignanciesAuthorship 10163825800760Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk SJournal of clinical oncology : official journal of the American Society of Clinical OncologyHuman Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. J Clin Oncol. 2015 May 20; 33(15):1688-96.J Clin Oncol2015-03-23T00:00:002015Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.LeukemiaStem Cell TransplantationMD AndersonRICHARD ECHAMPLINRICHARD E CHAMPLIN8508CHAMPLIN, RICHARD EProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorAuthorship 28004818Center for Cell & Gene Therapy25977584Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, Durett AG, Dakhova O, Savoldo B, Di Stasi A, Spencer DM, Lin YF, Liu H, Grilley BJ, Gee AP, Rooney CM, Heslop HE, Brenner MKBloodInducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13.Blood2015-05-14T00:00:002015Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation.27270177Ramos CA, Savoldo B, Torrano V, Ballard B, Zhang H, Dakhova O, Liu E, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Brenner MK, Heslop HE, Dotti GThe Journal of clinical investigationClinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.J Clin Invest2016-06-06T00:00:002016Clinical responses with T lymphocytes targeting malignancy-associated ? light chains.74Professor54Instructor14Associate Professor42Director47Distinguished Service ProfessorAuthorship 31684314Authorship 316844223979304Kramer MA, Grilley BJInternational journal of pharmaceutical compoundingGaining access to investigational drugs for treatment: an investigational new drug application primer. Int J Pharm Compd. 2002 Jul-Aug; 6(4):271-3.Int J Pharm Compd2002-07-01T00:00:002002Gaining access to investigational drugs for treatment: an investigational new drug application primer.1102 BATESHouston, 77030TX16249392Rousseau RF, Biagi E, Dutour A, Yvon ES, Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, Gee AP, Krance RA, Popat U, Carrum G, Margolin JF, Brenner MKBloodImmunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood. 2006 Feb 15; 107(4):1332-41.Blood2005-10-25T00:00:002005Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.12850787Grilley BJ, Gee APCytotherapyGene transfer: regulatory issues and their impact on the clinical investigator and the good manufacturing production facility. Cytotherapy. 2003; 5(3):197-207.Cytotherapy2003-01-01T00:00:002003Gene transfer: regulatory issues and their impact on the clinical investigator and the good manufacturing production facility.Authorship 320073126585503Grilley BJBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationEthical Considerations in Pediatric Stem Cell Donation. Biol Blood Marrow Transplant. 2016 Jan; 22(1):3.Biol Blood Marrow Transplant2015-11-14T00:00:002015Ethical Considerations in Pediatric Stem Cell Donation.12406881Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z, Smith SC, Inman S, Cooper K, Alcoser P, Grilley B, Gee A, Popek E, Davidoff A, Bowman LC, Brenner MK, Strother DBloodLocal and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003 Mar 01; 101(5):1718-26.Blood2002-10-24T00:00:002002Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma.Authorship 325200141814202Grilley BJ, Trissel LA, Bluml BMAmerican journal of hospital pharmacyDesign and implementation of an electronic investigational drug accountability system. Am J Hosp Pharm. 1991 Dec; 48(12):2616-8.Am J Hosp Pharm1991-12-01T00:00:001991Design and implementation of an electronic investigational drug accountability system.22047558Di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Savoldo B, Gee AP, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MKThe New England journal of medicineInducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 03; 365(18):1673-83.N Engl J Med2011-11-03T00:00:002011Inducible apoptosis as a safety switch for adoptive cell therapy.18034566Grilley BJ, Aguilar LK, Aguilar-Cordova EBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapyReporting adverse events in gene therapy studies. BioDrugs. 2000 Sep; 14(3):141-5.BioDrugs2000-09-01T00:00:002000Reporting adverse events in gene therapy studies.21540550Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti GThe Journal of clinical investigationCD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6.J Clin Invest2011-04-11T00:00:002011CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.Authorship 8691592528426845Ahmed N, Brawley V, Hegde M, Bielamowicz K, Kalra M, Landi D, Robertson C, Gray TL, Diouf O, Wakefield A, Ghazi A, Gerken C, Yi Z, Ashoori A, Wu MF, Liu H, Rooney C, Dotti G, Gee A, Su J, Kew Y, Baskin D, Zhang YJ, New P, Grilley B, Stojakovic M, Hicks J, Powell SZ, Brenner MK, Heslop HE, Grossman R, Wels WS, Gottschalk SJAMA oncologyHER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. JAMA Oncol. 2017 Aug 01; 3(8):1094-1101.JAMA Oncol2017-08-01T00:00:002017HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.9625264Roskrow MA, Rooney CM, Heslop HE, Brenner MK, Krance RA, Gresik MV, McClain K, Aguilar LK, Grilley B, Rob E, Carrum GHuman gene therapyAdministration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 1998 May 20; 9(8):1237-50.Hum Gene Ther1998-05-20T00:00:001998Administration of neomycin resistance gene marked EBV specific cytotoxic T-lymphocytes to patients with relapsed EBV-positive Hodgkin disease.Authorship 872811628602436Heczey A, Louis CU, Savoldo B, Dakhova O, Durett A, Grilley B, Liu H, Wu MF, Mei Z, Gee A, Mehta B, Zhang H, Mahmood N, Tashiro H, Heslop HE, Dotti G, Rooney CM, Brenner MKMolecular therapy : the journal of the American Society of Gene TherapyCAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224.Mol Ther2017-06-09T00:00:002017CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.10910143Heslop H, Rooney C, Brenner M, Krance R, Carrum G, Gahn B, Bollard C, Khan S, Gee A, Popat U, Gresik M, Przepiorka D, Kuehnle I, Grilley BHuman gene therapyAdministration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease. Hum Gene Ther. 2000 Jul 01; 11(10):1465-75.Hum Gene Ther2000-07-01T00:00:002000Administration of neomycin resistance gene-marked EBV-specific cytotoxic T-lymphocytes as therapy for patients receiving a bone marrow transplant for relapsed EBV-positive Hodgkin disease.10910144Brenner MK, Heslop H, Krance R, Horowitz M, Strother D, Nuchtern J, Grilley B, Martingano E, Cooper KHuman gene therapyPhase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.Hum Gene Ther2000-07-01T00:00:002000Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector.28783452Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, Carrum G, Sasa G, Lulla P, Watanabe A, Kuvalekar M, Gee AP, Wu MF, Liu H, Grilley BJ, Krance RA, Gottschalk S, Brenner MK, Rooney CM, Heslop HE, Leen AM, Omer BJournal of clinical oncology : official journal of the American Society of Clinical OncologyOff-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2017 Nov 01; 35(31):3547-3557.J Clin Oncol2017-08-07T00:00:002017Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.Authorship 87709615Authorship 8773231028805662Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, Bilgi M, Wu MF, Liu H, Grilley B, Bollard CM, Chang BH, Rooney CM, Brenner MK, Heslop HE, Dotti G, Savoldo BThe Journal of clinical investigationClinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017 Sep 01; 127(9):3462-3471.J Clin Invest2017-08-14T00:00:002017Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes.1830190Trissel LA, Tramonte SM, Grilley BJAmerican journal of hospital pharmacyVisual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm. 1991 May; 48(5):988-92.Am J Hosp Pharm1991-05-01T00:00:001991Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.16203783Biagi E, Rousseau R, Yvon E, Schwartz M, Dotti G, Foster A, Havlik-Cooper D, Grilley B, Gee A, Baker K, Carrum G, Rice L, Andreeff M, Popat U, Brenner MClinical cancer research : an official journal of the American Association for Cancer ResearchResponses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2005 Oct 01; 11(19 Pt 1):6916-23.Clin Cancer Res2005-10-01T00:00:002005Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.true1Associate ProfessorAssociate Professortrue1InstructorInstructorAuthorship 1058971D011948Chemicals & Drugs36211390.611894Receptors, Antigen, T-CellD018380Procedures55965180.273586Hematopoietic Stem Cell TransplantationD016219Procedures37817300.485472Immunotherapy, AdoptiveD009927Activities & BehaviorsObjectsProcedures892280.783911Tissue and Organ ProcurementD013601Anatomy82238320.393247T-LymphocytesCenter for Cell & Gene TherapyDepartment of MedicineDepartment of PediatricsMedicine-Hematology & OncologyPediatrics-Hem/Onc Cell & Gene ThePediatrics-Hematology & OncologyBaylor College of MedicineCARIDADMARTINEZCARIDAD MARTINEZ0.000000000000000.000000000000001408MARTINEZ, CARIDADAssociate Professor0.9425960.00682568218research areas1.686690.010415856coauthor of35.06556.2706860similar to1168selected publicationsCARLOSRAMOSCARLOS RAMOS0.000000000000000.000000000000002089RAMOS, CARLOSProfessorROBERTKRANCEROBERT KRANCE0.000000000000000.000000000000003557KRANCE, ROBERTProfessorMALCOLMBRENNERMALCOLM BRENNER0.000000000000000.000000000000003564BRENNER, MALCOLMDistinguished Service Professor30309819Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, Kamble RT, Gee AP, Mei Z, Wu MF, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Savoldo B, Dotti GMolecular therapy : the journal of the American Society of Gene TherapyIn?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.Mol Ther2018-09-13T00:00:002018In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.30262660McLaughlin LP, Rouce R, Gottschalk S, Torrano V, Carrum G, Wu MF, Hoq F, Grilley B, Marcogliese AM, Hanley PJ, Gee AP, Brenner MK, Rooney CM, Heslop HE, Bollard CMBloodEBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.Blood2018-09-27T00:00:002018EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation.CLIONAROONEYCLIONA ROONEY0.000000000000000.000000000000003578ROONEY, CLIONAProfessorADRIANGEEADRIAN GEE0.000000000000000.000000000000003642GEE, ADRIANProfessorSTACEYSHUBERTSTACEY SHUBERT0.000000000000000.000000000000004765SHUBERT, STACEYInstructorNABILAHMEDNABIL AHMED0.000000000000000.00000000000000613AHMED, NABILProfessorAuthorship 94066616HELENHESLOPHELEN HESLOP0.000000000000000.000000000000003566HESLOP, HELENProfessorAuthorship 9440718Authorship 1234837Authorship 1235489Authorship 12364414Authorship 12782018Authorship 1283641223610374Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, Dey BR, Grilley BJ, Gee AP, Brenner MK, Rooney CM, Heslop HEBloodMulticenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27; 121(26):5113-23.Blood2013-04-22T00:00:002013Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation.24030379Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, Gee AP, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti GBloodInfusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.Blood2013-09-12T00:00:002013Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.Authorship 951653931292125Abraham AA, John TD, Keller MD, Cruz CRN, Salem B, Roesch L, Liu H, Hoq F, Grilley BJ, Gee AP, Dave H, Jacobsohn DA, Krance RA, Shpall EJ, Martinez CA, Hanley PJ, Bollard CMBlood advancesSafety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients. Blood Adv. 2019 07 23; 3(14):2057-2068.Blood Adv2019-07-23T00:00:002019Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients.Authorship 10835812true1ProfessorProfessortrue1Distinguished Service ProfessorDistinguished Service Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessorPREMALLULLAPREMAL LULLA0.000000000000000.000000000000006046LULLA, PREMALAssociate Professortrue1ProfessorProfessorAuthorship 9944501832669548Hegde M, Joseph SK, Pashankar F, DeRenzo C, Sanber K, Navai S, Byrd TT, Hicks J, Xu ML, Gerken C, Kalra M, Robertson C, Zhang H, Shree A, Mehta B, Dakhova O, Salsman VS, Grilley B, Gee A, Dotti G, Heslop HE, Brenner MK, Wels WS, Gottschalk S, Ahmed NNature communicationsTumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat Commun. 2020 07 15; 11(1):3549.Nat Commun2020-07-15T00:00:002020Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma.Authorship 99510418Authorship 9956582032701411Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, Wang T, Shea TC, Rooney CM, Dittus C, Park SI, Gee AP, Eldridge PW, McKay KL, Mehta B, Cheng CJ, Buchanan FB, Grilley BJ, Morrison K, Brenner MK, Serody JS, Dotti G, Heslop HE, Savoldo BJournal of clinical oncology : official journal of the American Society of Clinical OncologyAnti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J Clin Oncol. 2020 11 10; 38(32):3794-3804.J Clin Oncol2020-07-23T00:00:002020Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.32727914Lulla PD, Tzannou I, Vasileiou S, Carrum G, Ramos CA, Kamble R, Wang T, Wu M, Bilgi M, Gee AP, Mukhi S, Chung B, Wang L, Watanabe A, Kuvalekar M, Jeong M, Li Y, Ketkar S, French-Kim M, Grilley B, Brenner MK, Heslop HE, Vera JF, Leen AMScience translational medicineThe safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. Sci Transl Med. 2020 07 29; 12(554).Sci Transl Med2020-07-29T00:00:002020The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma.Authorship 10062762033270816Lulla PD, Naik S, Vasileiou S, Tzannou I, Watanabe A, Kuvalekar M, Lulla S, Carrum G, Ramos CA, Kamble R, Hill L, Randhawa J, Gottschalk S, Krance R, Wang T, Wu M, Robertson C, Gee AP, Chung B, Grilley B, Brenner MK, Heslop HE, Vera JF, Leen AMBloodClinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.Blood2021-05-13T00:00:002021Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant.Authorship 10100481533507803Vasileiou S, Lulla PD, Tzannou I, Watanabe A, Kuvalekar M, Callejas WL, Bilgi M, Wang T, Wu MJ, Kamble R, Ramos CA, Rouce RH, Zeng Z, Gee AP, Grilley BJ, Vera JF, Bollard CM, Brenner MK, Heslop HE, Rooney CM, Leen AM, Carrum GJournal of clinical oncology : official journal of the American Society of Clinical OncologyT-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.J Clin Oncol2021-01-28T00:00:002021T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects.Authorship 1174401true1ProfessorProfessorAuthorship 103876217Authorship 10395851035134127Naik S, Vasileiou S, Tzannou I, Kuvalekar M, Watanabe A, Robertson C, Lapteva N, Tao W, Wu M, Grilley B, Carrum G, Kamble RT, Hill L, Krance RA, Martinez C, Tewari P, Omer B, Gottschalk S, Heslop HE, Brenner MK, Rooney CM, Vera JF, Leen AM, Lulla PDBloodDonor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL. Blood. 2022 04 28; 139(17):2706-2711.Blood2022-04-28T00:00:002022Donor-derived multiple leukemia antigen-specific T-cell therapy to prevent relapse after transplant?in patients with ALL.35325065Steffin DHM, Muhsen IN, Hill LC, Ramos CA, Ahmed N, Hegde M, Wang T, Wu M, Gottschalk S, Whittle SB, Lulla PD, Mamonkin M, Omer B, Rouce RH, Heczey A, Metelitsa LS, Grilley BJ, Robertson C, Torrano V, Lapteva N, Gee AP, Rooney CM, Brenner MK, Heslop HEBloodLong-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.Blood2022-07-07T00:00:002022Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs.Authorship 15401Authorship 1049712Authorship 1049713Authorship 1049714Authorship 1049715Authorship 1049716Authorship 1049717Authorship 1049718Grilley BJInvestigational Drugs in the Principles and Practice of Drug InformationDrug Information: A Guide for Pharmacists (McGraw-Hill). Investigational Drugs in the Principles and Practice of Drug Information. 2017; 933-975.2017-01-01T00:00:002017Drug Information: A Guide for Pharmacists (McGraw-Hill)Grilley BJIND Applications for Cellular Therapy ProductsCell Therapy: cGMP Facilities and Manufacturing (Springer). IND Applications for Cellular Therapy Products. 2022; 119-143.2022-01-01T00:00:002022Cell Therapy: cGMP Facilities and Manufacturing (Springer)Grilley BJThe Patient Advocate Role in Scientific ReviewThe Patient Advocate Role in Scientific Review. 2022.2022-01-01T00:00:002022The Patient Advocate Role in Scientific ReviewGrilley BJFDA and Drug DevelopmentFDA and Drug Development. 2022.2022-01-01T00:00:002022FDA and Drug DevelopmentGrilley BJEthics in the Treatment of Pediatric Cancer PatientsEthics in the Treatment of Pediatric Cancer Patients. 2022.2022-01-01T00:00:002022Ethics in the Treatment of Pediatric Cancer PatientsGrilley BJInvestigational Drugs in the Principles and Practice of Drug InformationDrug Information: A Guide for Pharmacists (McGraw-Hill). Investigational Drugs in the Principles and Practice of Drug Information. 2022; 1013-1057.2022-01-01T00:00:002022Drug Information: A Guide for Pharmacists (McGraw-Hill)Grilley BJHow a Clinical Trial is Opened at an InstitutionHow a Clinical Trial is Opened at an Institution. 2022.2022-01-01T00:00:002022How a Clinical Trial is Opened at an InstitutionAuthorship 10510191535860837Hoyos V, Vasileiou S, Kuvalekar M, Watanabe A, Tzannou I, Velazquez Y, French-Kim M, Leung W, Lulla S, Robertson C, Foreman C, Wang T, Bulsara S, Lapteva N, Grilley B, Ellis M, Osborne CK, Coscio A, Nangia J, Heslop HE, Rooney CM, Vera JF, Lulla P, Rimawi M, Leen AMTherapeutic advances in medical oncologyMulti-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer. Ther Adv Med Oncol. 2022; 14:17588359221107113.Ther Adv Med Oncol2022-07-15T00:00:002022Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer.Authorship 105440810Authorship 10570671036518078Cornetta K, Yao J, House K, Duffy L, Adusumilli PS, Beyer R, Booth C, Brenner M, Curran K, Grilley B, Heslop H, Hinrichs CS, Kaplan RN, Kiem HP, Kochenderfer J, Kohn DB, Mailankody S, Norberg SM, O'Cearbhaill RE, Pappas J, Park J, Ramos C, Ribas A, Rivi?re I, Rosenberg SA, Sauter C, Shah NN, Slovin SF, Thrasher A, Williams DA, Lin TYMolecular therapy : the journal of the American Society of Gene TherapyReplication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials. Mol Ther. 2023 03 01; 31(3):801-809.Mol Ther2022-12-14T00:00:002022Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials.36373249Vasileiou S, Hill L, Kuvalekar M, Workineh AG, Watanabe A, Velazquez Y, Lulla S, Mooney K, Lapteva N, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Eagar TN, Carrum G, Grimes KA, Leen AM, Lulla PHaematologicaAllogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients. Haematologica. 2023 Jul 01; 108(7):1840-1850.Haematologica2023-07-01T00:00:002023Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients.true1Associate ProfessorAssociate ProfessorAuthorship 10674581136989357Wang D, Porter CE, Lim B, Rosewell Shaw A, Robertson CS, Woods ML, Xu Y, Biegert GGW, Morita D, Wang T, Grilley BJ, Heslop H, Brenner MK, Suzuki MScience advancesUltralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies. Sci Adv. 2023 03 29; 9(13):eade6790.Sci Adv2023-03-29T00:00:002023Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies.Authorship 1068653537097267Zettler PJ, Ikonomou L, Levine AD, Turner L, Grilley B, Roxland BECytotherapyAn International Society for Cell & Gene Therapy working group short report on the future of expanded access to unapproved cell and gene therapies. Cytotherapy. 2023 07; 25(7):712-717.Cytotherapy2023-04-25T00:00:002023An International Society for Cell & Gene Therapy working group short report on the future of expanded access to unapproved cell and gene therapies.37188782Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, Li Y, Zhang C, Demberg T, Di Pierro EJ, Sher AC, Zhang H, Mehta B, Thakkar SG, Grilley B, Wang T, Weiss BD, Montalbano A, Subramaniam M, Xu C, Sachar C, Wells DK, Dotti G, Metelitsa LSNature medicineAnti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023 Jun; 29(6):1379-1388.Nat Med2023-05-15T00:00:002023Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.Authorship 107079119Authorship 1076620437517865Ikonomou L, Cuende N, Forte M, Grilley BJ, Levine AD, Munsie M, Rasko JEJ, Turner L, Bidkhori HR, Ciccocioppo R, Grignon F, Srivastava A, Weiss DJ, Zettler P, Levine BL, ISCT Committee on the Ethics of Cell and Gene Therapy (ECGT)CytotherapyInternational Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products. Cytotherapy. 2023 09; 25(9):920-929.Cytotherapy2023-09-01T00:00:002023International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products.true1ProfessorProfessor2ProfessorProfessorAuthorship 108584217Authorship 1085869738145560Hill LC, Rouce RH, Wu M, Wang T, Ma R, Zhang H, Mehta B, Lapteva N, Mei Z, Smith TS, Yang L, Srinivasan M, Burkhardt PM, Ramos CA, Lulla PD, Arredondo M, Grilley B, Heslop HE, Brenner MK, Mamonkin MBloodAnti-tumor Efficacy and Safety of Unedited Autologous CD5.CAR T cells in Relapsed/Refractory Mature T-cell Lymphomas. Blood. 2023 Dec 25.Blood2023-12-25T00:00:002023Anti-tumor Efficacy and Safety of Unedited Autologous CD5.CAR T cells in Relapsed/Refractory Mature T-cell Lymphomas.38149948Kapadia CD, Rosas G, Thakkar SG, Wu M, Torrano V, Wang T, Grilley BJ, Heslop HE, Ramos CA, Goodell MA, Lulla PDCytotherapyIncipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy. Cytotherapy. 2024 Mar; 26(3):261-265.Cytotherapy2023-12-26T00:00:002023Incipient clonal hematopoiesis is accelerated following CD30.CAR-T therapy.Authorship 10867191938195754Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, Li Y, Zhang C, Demberg T, Di Pierro EJ, Sher AC, Zhang H, Mehta B, Thakkar SG, Grilley B, Wang T, Weiss BD, Montalbano A, Subramaniam M, Xu C, Sachar C, Wells DK, Dotti G, Metelitsa LSNature medicineAuthor Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2024 Jan 09.Nat Med2024-01-09T00:00:002024Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.true1ProfessorProfessortrue1ProfessorProfessor24753538Zhou X, Di Stasi A, Tey SK, Krance RA, Martinez C, Leung KS, Durett AG, Wu MF, Liu H, Leen AM, Savoldo B, Lin YF, Grilley BJ, Gee AP, Spencer DM, Rooney CM, Heslop HE, Brenner MK, Dotti GBloodLong-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905.Blood2014-04-21T00:00:002014Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene.Authorship 14404313Authorship 5735610Authorship 864853Authorship 9693210Authorship 722936